AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?
The Motley FoolThe big pharma company’s top drug is losing ground, but its dividend keeps rising.
The big pharma company’s top drug is losing ground, but its dividend keeps rising.